source
- AI-focused biotech firms drive biopharma toward a 'fail-fast' drug development modelAI is quickly becoming a central force in drug development as tech capital pours into biopharma, reshaping how new medicines are discovered. Tyrone Lam, chief business officer at GATC Health, says…
- Scholar Rock pulls Indiana fill-finish plant from SMA therapy filing after FDA flags violationsScholar Rock has removed Novo Nordisk's former Catalent fill‑finish facility in Bloomington, Indiana, from its regulatory filing for a spinal muscular atrophy therapy after the FDA classified the p…